HuR Confers Resistance of Hepatocellular Carcinoma to Lenvatinib by Inhibiting Ferroptosis
- 1Key Laboratory of Tropical Translational Medicine, Ministry of Education, Hainan Provincial Key Laboratory of Carcinogenesis and Intervention, School of Basic Medical Sciences Hainan Medical University Haikou Hainan Province P.R. China
- 2Department of Medical Oncology The Second Affiliated Hospital of Hainan Medical University Haikou Hainan Province P.R. China
Abstract
This study aim to explore whether human antigen R (HuR) inhibits ferroptosis confers resistance to lenvatinib in hepatocellular carcinoma (HCC). Bioinformatics analysis and immunofluorescence detection of 30 HCC tissue samples were used to verify the clinical correlation between HuR and glutathione peroxidase 4 (GPX4), establish a lenvatinib‐resistant HCC cell line, and evaluate the cell phenotypes and ferroptosis indicators (Fe2+, reactive oxygen species (ROS), lipid peroxidation, glutathione (GSH)) through functional experiments. The HuR‐GPX4 axis was analysed by genetic intervention methods and verified through xenograft mouse tumour models. Co‐expression of HuR/GPX4 in HCC tissues was associated with poor prognosis. Under lenvatinib treatment, the drug‐resistant cell lines showed increased malignant behaviour and ferroptosis resistance characteristics (decreased ferrous ions, ROS, lipid peroxidation, and increased GSH) in HCC cells, as well as upregulation of lenvatinib targeting vascular endothelial growth factor receptor 1 (VEGFR1)/fibroblast growth factor receptor 3 (FGFR3). HuR promotes the expression of GPX4 via cytoplasmic translocation. Interference with the expression of HuR could reverse the drug resistance phenotype and increase ferroptosis in lenvatinib‐induced HCC; overexpression of GPX4 partially restored drug resistance. HuR is an important molecule for conferring resistance to lenvatinib therapy and may be involved in inhibiting ferroptosis by upregulating the expression and activity of GPX4. This study provides a new strategy for targeting patients with HCC.
Related
- Tumor-derived annexin A1 drives lenvatinib resistance by regulating SOX2/STAT3/S100A6 feedback loop and M2 macrophage polarization in hepatocellular carcinoma
- CD36-Mediated Lipid Metabolic Reprogramming in Hepatocellular Carcinoma: Crosstalk With Immunity, Ferroptosis, and Therapeutic Resistance.
- PSAT1 integrates ferroptosis resistance and immune evasion to drive hepatocellular carcinoma progression
- Survival outcomes of spleen-strengthening and dampness-eliminating traditional Chinese medicine granules combined with lenvatinib for unresectable hepatocellular carcinoma: a large-sample retrospective study based on electronic medical records
- Hepatic arterial infusion chemotherapy plus lenvatinib and programmed death receptor 1 inhibitor for hepatocellular carcinoma with portal vein tumor thrombosis: a prospective controlled study
BibTeX
@article{feng2026confers,
title = {{HuR Confers Resistance of Hepatocellular Carcinoma to Lenvatinib by Inhibiting Ferroptosis}},
author = {Siren Feng and Fang Wang and Huayi Wu and Xinran Lin and Xue Qi and Kun Liu and Qiushi Yin and Bo Lin and Mengsen Li and Mingyue Zhu},
journal = {Journal of Cellular and Molecular Medicine},
year = {2026},
month = nov,
doi = {10.1111/jcmm.71423},
url = {https://doi.org/10.1111/jcmm.71423},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - HuR Confers Resistance of Hepatocellular Carcinoma to Lenvatinib by Inhibiting Ferroptosis
AU - Siren Feng
AU - Fang Wang
AU - Huayi Wu
AU - Xinran Lin
AU - Xue Qi
AU - Kun Liu
AU - Qiushi Yin
AU - Bo Lin
AU - Mengsen Li
AU - Mingyue Zhu
PY - 2026
DA - 2026/11/03
JO - Journal of Cellular and Molecular Medicine
DO - 10.1111/jcmm.71423
UR - https://doi.org/10.1111/jcmm.71423
AB - This study aim to explore whether human antigen R (HuR) inhibits ferroptosis confers resistance to lenvatinib in hepatocellular carcinoma (HCC). Bioinformatics analysis and immunofluorescence detection of 30 HCC tissue samples were used to verify the clinical correlation between HuR and glutathione peroxidase 4 (GPX4), establish a lenvatinib‐resistant HCC cell line, and evaluate the cell phenotypes and ferroptosis indicators (Fe2+, reactive oxygen species (ROS), lipid peroxidation, glutathione (GSH)) through functional experiments. The HuR‐GPX4 axis was analysed by genetic intervention methods and verified through xenograft mouse tumour models. Co‐expression of HuR/GPX4 in HCC tissues was associated with poor prognosis. Under lenvatinib treatment, the drug‐resistant cell lines showed increased malignant behaviour and ferroptosis resistance characteristics (decreased ferrous ions, ROS, lipid peroxidation, and increased GSH) in HCC cells, as well as upregulation of lenvatinib targeting vascular endothelial growth factor receptor 1 (VEGFR1)/fibroblast growth factor receptor 3 (FGFR3). HuR promotes the expression of GPX4 via cytoplasmic translocation. Interference with the expression of HuR could reverse the drug resistance phenotype and increase ferroptosis in lenvatinib‐induced HCC; overexpression of GPX4 partially restored drug resistance. HuR is an important molecule for conferring resistance to lenvatinib therapy and may be involved in inhibiting ferroptosis by upregulating the expression and activity of GPX4. This study provides a new strategy for targeting patients with HCC.
SN - 1582-1838
SN - 1582-4934
ER -